2-amino-2,3-dimethylbutan-1-ol | 13893-62-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-amino-2,3-dimethylbutan-1-ol
• CAS: 13893-62-4
• 化学式: C₆H₁₅NO
• mdl: MFCD16769960
• 分子量: 117.191
• InChiKey: NDBACGDBUINENU-UHFFFAOYSA-N

物化性质

• 沸点：
  198.5±13.0 °C(Predicted)
• 密度：
  0.907±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-amino-2,3-dimethylbutan-1-ol 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.17h， 生成 tert-butyl 4-isopropyl-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide
  参考文献：
  名称：

  [EN] PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
  [FR] DÉRIVÉS DE PYRIDINAMINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DES CANAUX POTASSIQUES

  摘要：

  The present disclosure is directed to compounds of Formula (I): wherein m, n, Y, R1, R2, R3, R4and R5are each as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of Formula (I), as described herein, which are useful as voltage-gated potassium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

  公开号：

  WO2023239729A1
• 作为产物：
  描述：

  乙基3-甲基-D-异缬氨酸酯 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 2-amino-2,3-dimethylbutan-1-ol
  参考文献：
  名称：

  α-氨基酸在2-氨基乙硫醇衍生物的合成中作为潜在的抗辐射剂的用途。

  摘要：

  DOI：

  10.1021/jm00324a027

文献信息

• NOVEL PYRIDINE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20120316147A1

  公开（公告）日：2012-12-13

  The invention relates to a compound of formula (I) wherein R 1 to R 4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种公式(I)的化合物 其中R1至R4定义如描述和权利要求中所述。公式(I)的化合物可作为药物使用。
• Dihydrothienopyrimidines for the Treatment of Inflammatory Diseases
  申请人：Pouzet Pascale

  公开号：US20080096882A1

  公开（公告）日：2008-04-24

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  该发明涉及公式1的新二氢噻吡嘧啶，以及其药理学上可接受的盐、对映体、旋光异构体、消旋体、水合物或溶剂合物，其中X为SO或SO2，但最好为SO，R1、R2和R3在描述中给出的含义，并且适用于治疗呼吸道或胃肠道疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的药物组合物。
• Dihydrothienopyrimidines for the treatment of inflammatory Diseases
  申请人：POUZET Pascale

  公开号：US20120108534A1

  公开（公告）日：2012-05-03

  The invention relates to new dihydrothienopyrimidine of formula 1 , as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  本发明涉及一种新的二氢噻唑嘧啶化合物，其化学式为1，以及其药物学上可接受的盐、对映异构体、对映体、外消旋体、水合物或溶剂化物，其中X为SO或SO2，但优选为SO，R1、R2和R3在说明中给出了其含义，该化合物适用于治疗呼吸或胃肠道不适或疾病、关节、皮肤或眼睛的炎症性疾病、周围或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。
• 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases
  申请人：POUZET Pascale

  公开号：US20140005154A1

  公开（公告）日：2014-01-02

  The invention relates to new dihydrothienopyrimidine of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein X is SO or SO 2 , but preferably SO, and wherein R 1 , R 2 and R 3 have the meanings given in the description, and which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

  本发明涉及式1的新的二氢噻唑嘧啶，以及其药学上可接受的盐、对映异构体、对映体混合物、水合物或溶剂化物，其中X为SO或SO2，但优选为SO，R1、R2和R3具有所述描述中给出的含义，适用于治疗呼吸或消化不适或疾病、关节、皮肤或眼睛的炎症性疾病、外周或中枢神经系统疾病或癌症，以及含有这些化合物的制药组合物。
• Chip-resistant composite coating
  申请人：BASF CORPORATION

  公开号：EP0602559A2

  公开（公告）日：1994-06-22

  A coated article is described comprising a substrate having thereon a color-plus-clear composite coating wherein (a) the color layer of the composite coating is derived from a coating composition comprising: (1) a polymer component having active hydrogen-containing groups thereon, (2) an aminoplast curing agent, (3) an acid cure catalyst, and (4) an amine selected from the group consisting of substituted or unsubstituted pyridine or a substituted or unsubstituted N-alkyl primary amine, and (b) the clear layer of the composite coating is derived from a curable coating composition comprising an epoxy-functional component and an acid-functional or anhydride-functional component.

  描述了一种涂层制品，该制品包括基材，基材上有一层彩色加透明的复合涂层，其中 (a) 复合涂层的色层来自涂层组合物，该涂层组合物包括 (1) 具有活性含氢基团的聚合物成分、 (2) 一种氨基固化剂、 (3) 酸固化催化剂，和 (4) 选自取代或未取代的吡啶或取代或未取代的 N-烷基伯胺的胺，以及 (b) 复合涂层的透明层来自可固化涂层组合物，该组合物包括环氧官能团和酸官能团或酸酐官能团。